Corporation
Hoffmann-La Roche Limited
- Meetings this Parliament
- 26
- With MPs
- 10
- Since Nov 2021
- 168
- Active registrations
- 1
Most recent reported meeting: Sep 29, 2026.
Lobbying by Hoffmann-La Roche Limited: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingWho they meet
Since the current Parliament opened.
MPs
- Jagsharan Singh Mahal Conservative 2
- Karim Bardeesy Liberal 2
- Marjorie Michel Liberal 2
- Burton Bailey Conservative 1
- Kurt Holman Conservative 1
- Aslam Rana Liberal 1
- Maggie Chi Liberal 1
- Charles Sousa Liberal 1
- Brendan Hanley Liberal 1
- Yasir Naqvi Liberal 1
- Helena Jaczek Liberal 1
- Matt Jeneroux Liberal 1
Institutions
- Innovation, Science and Economic Development Canada (ISED)12
- House of Commons11
- Health Canada (HC)11
- Treasury Board Of Canada Secretariat (TBS)6
- Finance Canada (FIN)5
- Prime Minister's Office (PMO)2
- Intergovernmental Affairs Secretariat (IGA)2
- Public Services and Procurement Canada (PSPC)1
Registrations in effect
In-house (corporation) In effect since Sep 30, 2026
Filed by Stefanos Tsamousis, PRESIDENT AND CHIEF EXECUTIVE OFFICER
Lobbyists
- Bill Zindle · Executive Director, Strategy and Marketing
- Cassondra McCrory · Healthcare System Partner Federal
- Donna Janzen · Director Regulatory Strategy & Policy
- Michele D'Elia · Executive Director, Medical & Scientific Affairs
- Roger Tam · Vice President, Legal
- Shikha Virdi · Chapter Lead, Policy & Healthcare Ecosystems
- Stefanos Tsamousis · PRESIDENT AND CHIEF EXECUTIVE OFFICER
Institutions they may lobby: Canadian Institutes of Health Research (CIHR), Environment and Climate Change Canada (ECCC), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (15)Hide details
- The Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of importation legislation in the United States.
- Pharmaceutical intellectual property protection as it relates to international trade agreements
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.
- Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
- Food and Drugs Act updates, as it relate to the reform of clinical trial applications, and drug/device submission review and approval process. Scope includes new drug submissions/indications and post market submissions, reliance & recognition pathways, service standards, fees, biosimilars, clinical trial modernization.
- Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
- Standing Committee on Finance (FINA) as it relates to pre-budget consultations.
- The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy.
- Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
- Income Tax Act as it relates to biopharmaceutical industry.
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
- House of Commons Standing Committee of Industry and Technology (INDU) as it relates to Artificial Intelligence and/or any other pertinent legislative proposal before the committee
- Patented Medicines Prices Review Board (PMPRB), as it relates to reporting requirements, pricing guidelines, and dispute resolution
- Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
- Clinical Trials environment in Canada: operational issues, investment, enrollment
Registration 966507-64-73. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Brigitte Nolet (114), Ronnie Miller (39), Stefanos Tsamousis (8), Dan Edgcumbe (7).
-
Reported by Stefanos Tsamousis · In-house (corporation)
- Yasir Naqvi · Member of Parliament
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
-
Reported by Stefanos Tsamousis · In-house (corporation)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
-
Reported by Stefanos Tsamousis · In-house (corporation)
- Julie Harb · Senior Policy Advisor, Prime Minister's Office (PMO)
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Stefanos Tsamousis · In-house (corporation)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
-
Reported by Stefanos Tsamousis · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Read more
-
Reported by Stefanos Tsamousis · In-house (corporation)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
-
Reported by Stefanos Tsamousis · In-house (corporation)
- Scott Winter · Director General, Finance Canada (FIN)
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Dan Edgcumbe · In-house (corporation)
- Julie Harb · Senior Policy Advisor, Prime Minister's Office (PMO)
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Dan Edgcumbe · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director, Life Science Industries Directorate, Innovation, Science and Economic Development Canada (ISED)
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
-
Reported by Dan Edgcumbe · In-house (corporation)
- Aslam Rana · Member of Parliament, Hamilton Centre
- Reza Arianne · Deputy Minister, Public Services and Procurement Canada (PSPC)
- Joelle Paquette · Associate Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
-
Reported by Dan Edgcumbe · In-house (corporation)
- Kaili Levesque · Associate Deputy Minister, Fisheries and Oceans Canada (DFO)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Linsey Hollett · Assistant deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
and 6 moreShow fewer
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Curtis-Micallef Shalene · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
-
Reported by Stefanos Tsamousis · In-house (corporation)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
and 5 moreShow fewer
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- Jibril Hussein · Senior Policy Advisor, House of Commons
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Linsey Hollett · Assistant deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
-
Reported by Dan Edgcumbe · In-house (corporation)
- Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 6 moreShow fewer
- Annahat Kochar · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
- Sara O'Connor · AADM, Health Canada (HC)
- Celia Lourenco · AADM, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Dan Edgcumbe · In-house (corporation)
- Maggie Chi · Member of Parliament
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 7 moreShow fewer
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Dan Edgcumbe · In-house (corporation)
- Marjorie Michel · Minister of Health
- Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
and 6 moreShow fewer
- Linsey Hollett · Assistant deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director, Life Science Industries Directorate, Innovation, Science and Economic Development Canada (ISED)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Brigitte Nolet · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Marjorie Michel · Minister of Health
- Karim Bardeesy · Member of Parliament
- Janice Charette · Chief Trade Negotiator to the United States, House of Commons
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Assistant Associate Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED). Read more
-
Reported by Brigitte Nolet · In-house (corporation)
- Jagsharan Singh Mahal · MP Edmonton SouthEast
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Brigitte Nolet · In-house (corporation)
- Jagsharan Singh Mahal · MP Edmonton South East
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Brigitte Nolet · In-house (corporation)
- Karim Bardeesy · Parliamentary Secretary Assistant, Innovation, Science and Economic Development Canada (ISED)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Hosai Zurmati Halim · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 5 moreShow fewer
- Chase Knight · Parliamentary Secretary Assistant and Parliamentary Affairs Advisor, Innovation, Science and Economic Development Canada (ISED)
- Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Victoria Morton · Senior Communications Advisor, House of Commons
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Brigitte Nolet · In-house (corporation)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
Health Canada/PMPRB proposed regulation changes to the Patented Medicines Regulations.
-
Reported by Brigitte Nolet · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
-
Reported by Brigitte Nolet · In-house (corporation)
- Matt Jeneroux · Member of Parliament
Clinical Trials environment in Canada: operational issues, investment, enrollment
-
Reported by Brigitte Nolet · In-house (corporation)
- Francis Scarpaleggia · Member of Parliament
- Helena Jaczek · MP Markham-Stouffville
- Brendan Hanley · Member of Parliament
- Burton Bailey · MP, Red Deer
and 3 moreShow fewer
- Kurt Holman · MP London-Fanshawe
- Corey Tochor · Member of Parliament
- Charles Sousa · MP Mississauga-Lakeshore
Clinical Trials environment in Canada: operational issues, investment, enrollment
-
Reported by Brigitte Nolet · In-house (corporation)
- Manuela Tomic · Senior ADvisor, Innovation, Science and Economic Development Canada (ISED)
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Read more
-
Reported by Brigitte Nolet · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Read more
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.